
Sign up to save your podcasts
Or


A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.
In this episode, we speak to South African HIV doctor and scientist Linda-Gail Bekker at the University of Cape Town about her involvement in one of the trials for lenacapavir and why she thinks it could be so ground-breaking.
This episode was written and produced by Mend Mariwany and sound design was by Michelle Macklem. Gemma Ware is the executive producer. Our theme music is by Neeta Sarl. Full credits for this episode are available. Sign up here for a free daily newsletter from The Conversation.
If you like the show, please consider donating to The Conversation, which is an independent, not-for-profit news organisation. And please do rate and review the show wherever you listen.
By The Conversation4.7
5656 ratings
A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.
In this episode, we speak to South African HIV doctor and scientist Linda-Gail Bekker at the University of Cape Town about her involvement in one of the trials for lenacapavir and why she thinks it could be so ground-breaking.
This episode was written and produced by Mend Mariwany and sound design was by Michelle Macklem. Gemma Ware is the executive producer. Our theme music is by Neeta Sarl. Full credits for this episode are available. Sign up here for a free daily newsletter from The Conversation.
If you like the show, please consider donating to The Conversation, which is an independent, not-for-profit news organisation. And please do rate and review the show wherever you listen.

100 Listeners

76 Listeners

93 Listeners

15 Listeners

8 Listeners

42 Listeners

132 Listeners

61 Listeners

62 Listeners

15 Listeners

2 Listeners

8 Listeners

1 Listeners

304 Listeners

72 Listeners

0 Listeners

119 Listeners

4 Listeners

164 Listeners

242 Listeners

0 Listeners

0 Listeners

0 Listeners

12 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

49 Listeners

5 Listeners

48 Listeners

3 Listeners

0 Listeners